Tyme

Tyme is a biotechnology company headquartered in Bedminster, New Jersey. The company employs 10 individuals and generates an estimated $27.5 million in annual revenue. Tyme specializes in developing cancer metabolism-based therapies (CMBTs™) designed to combat a wide range of tumor types with minimal toxicity. Their approach focuses on exploiting the inherent metabolic vulnerabilities of cancer cells, inducing cell death through oxidative stress and stimulating the body's natural immune response. The company's lead compound, SM-88, has shown promising early clinical results in treating advanced cancers such as pancreatic, prostate, sarcomas, and breast cancer. This success reinforces Tyme's belief in the potential of their emerging CMBT™ pipeline. For more information about Tyme and their groundbreaking therapies, visit www.tymeinc.com.